Create Account | Sign In: Author or Forum

 
News  |  Journals  |  Conferences  |  Blogs  |  Articles  |  Forums  |  Twitter    
 
Category: Endocrinology | Family Medicine | Geriatrics | Gynecology | Nursing | Oncology | Pharmacy | Journal

Back to Journal Articles

Design Flaws Cast Doubt on Million Woman Study

Last Updated: January 19, 2012.

 

Evidence review suggests that study findings do not adequately satisfy principle of causation

Share |

Comments: (0)

Tell-a-Friend

 

  Related
 
The largest study linking hormone replacement therapy to breast cancer, the Million Women Study, had flaws in its design and the findings do not satisfy the principles of causation, according to an evidence review published online Jan. 16 in the Journal of Family Planning & Reproductive Health Care.

THURSDAY, Jan. 19 (HealthDay News) -- The largest study linking hormone replacement therapy (HRT) to breast cancer, the Million Women Study (MWS), had flaws in its design and the findings do not satisfy the principles of causation, according to an evidence review published online Jan. 16 in the Journal of Family Planning & Reproductive Health Care.

Samuel Shapiro, Ph.D., of the University of Cape Town in South Africa, and colleagues assessed the evidence for causality for estrogen plus progestogen (E+P) and for unopposed estrogen therapy (ET) in the MWS, using generally accepted causal criteria.

The researchers found that the findings for E+P and for ET did not sufficiently satisfy the criteria for time order, information and detection bias, confounding, statistical stability and strength of correlation, duration-response, internal and external consistency, or biological plausibility, in spite of the massive size of the MWS. The apparent risks reported would have been nullified had detection bias resulted in the identification of 0.3 additional cases of breast cancer in ET users (women aged 50 to 55 years) per 1,000 per year, or 1.2 cases in E+P users.

"HRT may or may not increase the risk of breast cancer, but the MWS did not establish that it does," the authors conclude.

Several authors disclosed financial ties to the manufacturers of products mentioned in the review.

Abstract
Full Text (subscription or payment may be required)

Copyright © 2012 HealthDay. All rights reserved.


Previous: ASCO: PAM4-Antigen Detects Early Pancreatic Cancer Next: Contraceptives Eschewed by Half of Teenage Mothers

Reader comments on this article are listed below. Review our comments policy.


Submit your opinion:

Name:

Email:

Location:

URL:

Remember my personal information

Notify me of follow-up comments?

advertisement.gif (61x7 -- 0 bytes)
 

Are you a Doctor, Pharmacist, PA or a Nurse?

Join the Doctors Lounge online medical community

  • Editorial activities: Publish, peer review, edit online articles.

Doctors Lounge Membership Application

 
     

 advertisement.gif (61x7 -- 0 bytes)

 

 

Useful Sites
MediLexicon
  Tools & Services: Follow DoctorsLounge on Twitter Follow us on Twitter | RSS News | Newsletter | Contact us
Copyright © 2001-2014
Doctors Lounge.
All rights reserved.

Medical Reference:
Diseases | Symptoms
Drugs | Labs | Procedures
Software | Tutorials

Advertising
Links | Humor
Forum Archive
CME | Conferences

Privacy Statement
Terms & Conditions
Editorial Board
About us | Email

This website is certified by Health On the Net Foundation. Click to verify. This site complies with the HONcode standard for trustworthy health information:
verify here.